2018
DOI: 10.21577/0103-5053.20180081
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Some simple reactions using commercially available chemicals were used in the preparation of new biologically remarkable quinoxaline 1,4-dioxide derivatives. Several steps performed on 4-chloro-2-nitroaniline resulted in a quinoxaline 1,4-dioxide derivative, which reacted with dimethylformamide dimethylacetal (DMF-DMA) to produce an enamine. Transamination of this enamine with anilines gave the fused 1,2-dihydropyrido[3,4-b]quinoxaline 5,10-dioxide derivatives via an addition-elimination mechanism. Basic conde… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 28 publications
(36 reference statements)
0
1
0
Order By: Relevance
“…In addition, a phase II clinical trial for the anticancer drug Tirapazamine (3‐amino‐1,2,4‐benzotriazine‐1,4 dioxide) was recently accomplished (Covens et al, 2006; Maluf et al, 2006). Even though QdNOs are still in the research stage, they have been shown to have a lot of therapeutic potential (Said et al, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…In addition, a phase II clinical trial for the anticancer drug Tirapazamine (3‐amino‐1,2,4‐benzotriazine‐1,4 dioxide) was recently accomplished (Covens et al, 2006; Maluf et al, 2006). Even though QdNOs are still in the research stage, they have been shown to have a lot of therapeutic potential (Said et al, 2018).…”
Section: Introductionmentioning
confidence: 99%